109 related articles for article (PubMed ID: 1592363)
41. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma.
Rajkumar SV; Fonseca R; Lacy MQ; Witzig TE; Therneau TM; Kyle RA; Litzow MR; Gertz MA; Greipp PR
J Clin Oncol; 1999 May; 17(5):1551-7. PubMed ID: 10334543
[TBL] [Abstract][Full Text] [Related]
42. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
43. Flow cytometric analysis of Ki-67 in invasive ductal carcinoma of the breast: correlation with tumor and patient characteristics.
Steck K; Hunt K; Tucker S; Singletary S; El-Naggar AK
Oncol Rep; 1999; 6(4):835-8. PubMed ID: 10373666
[TBL] [Abstract][Full Text] [Related]
44. Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort.
Møller HE; Preiss BS; Pedersen P; Kristensen IB; Hansen CT; Frederiksen M; Abildgaard N; Møller MB
APMIS; 2015 Aug; 123(8):652-8. PubMed ID: 26152595
[TBL] [Abstract][Full Text] [Related]
45. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation.
Pruneri G; Carboni N; Baldini L; Intini D; Colombi M; Bertolini F; Valentini S; Maisonneuve P; Viale G; Neri A
Hum Pathol; 2003 Jan; 34(1):41-7. PubMed ID: 12605365
[TBL] [Abstract][Full Text] [Related]
46. Growth fraction in non-small cell lung cancer estimated by proliferating cell nuclear antigen and comparison with Ki-67 labeling and DNA flow cytometry data.
Fontanini G; Pingitore R; Bigini D; Vignati S; Pepe S; Ruggiero A; Macchiarini P
Am J Pathol; 1992 Dec; 141(6):1285-90. PubMed ID: 1361306
[TBL] [Abstract][Full Text] [Related]
47. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness.
Gasparini G; Pozza F; Meli S; Reitano M; Santini G; Bevilacqua P
Anticancer Res; 1991; 11(6):2015-21. PubMed ID: 1776834
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of proliferating cells in acute leukemia with antibodies to proliferating cell nuclear antigen and Ki-67 monoclonal antibodies.
Inoue T; Yamane T; Park K; Im T; Tatsumi N; Okuda K
Arch Pathol Lab Med; 1993 Oct; 117(10):969-72. PubMed ID: 8105766
[TBL] [Abstract][Full Text] [Related]
49. Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers.
Henriksen R; Strang P; Backstrom T; Wilander E; Tribukait B; Oberg K
Anticancer Res; 1994; 14(2B):603-8. PubMed ID: 8010717
[TBL] [Abstract][Full Text] [Related]
50. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
Ak I; Gulbas Z
Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
[TBL] [Abstract][Full Text] [Related]
51. Immunophenotypic aberrations, DNA content, and cell cycle analysis of plasma cells in patients with myeloma and monoclonal gammopathies.
Lima M; Teixeira Mdos A; Fonseca S; Gonçalves C; Guerra M; Queirós ML; Santos AH; Coutinho A; Pinho L; Marques L; Cunha M; Ribeiro P; Xavier L; Vieira H; Pinto P; Justiça B
Blood Cells Mol Dis; 2000 Dec; 26(6):634-45. PubMed ID: 11358356
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of AgNOR and Ki-67 antigen as cell kinetic parameters in oral dysplasias and carcinomas.
Zoeller J; Flentje M; Sinn P; Born IA
Anal Cell Pathol; 1994 Jul; 7(1):77-88. PubMed ID: 7981138
[TBL] [Abstract][Full Text] [Related]
53. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.
Lin P; Owens R; Tricot G; Wilson CS
Am J Clin Pathol; 2004 Apr; 121(4):482-8. PubMed ID: 15080299
[TBL] [Abstract][Full Text] [Related]
54. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis.
Sahin AA; Ro J; Ro JY; Blick MB; el-Naggar AK; Ordonez NG; Fritsche HA; Smith TL; Hortobagyi GN; Ayala AG
Cancer; 1991 Aug; 68(3):549-57. PubMed ID: 1648433
[TBL] [Abstract][Full Text] [Related]
55. DNA ploidy, proliferation, and neu-oncogene protein overexpression in breast carcinoma.
Lee AK; Wiley B; Loda M; Bosari S; Dugan JM; Hamilton W; Heatley GJ; Cook L; Silverman ML
Mod Pathol; 1992 Jan; 5(1):61-7. PubMed ID: 1347424
[TBL] [Abstract][Full Text] [Related]
56. DNA index, cellular proliferative activity and nucleolar organizer regions in cancers of the larynx.
Cappiello J; Nicolai P; Antonelli AR; Facchetti F; Cadei M; Cornacchiari A; Grigolato PG
Eur Arch Otorhinolaryngol; 1995; 252(6):353-8. PubMed ID: 8679155
[TBL] [Abstract][Full Text] [Related]
57. Flow cytometric quantification of the proliferation-associated nuclear antigen p105 and DNA content in advanced head & neck cancers: results of RTOG 91-08.
Fu KK; Hammond E; Pajak TF; Clery M; Doggett RL; Byhardt RW; McDonald S; Cooper JS
Int J Radiat Oncol Biol Phys; 1994 Jul; 29(4):661-71. PubMed ID: 7913703
[TBL] [Abstract][Full Text] [Related]
58. [Detection of myeloma cells in peripheral blood using multi-parameter flow cytometry: monitoring residual disease].
Klabusay M; Doubek M; Adam Z; Hájek R; Krivanová A
Cas Lek Cesk; 2000 Jul; 139(14):432-6. PubMed ID: 11048405
[TBL] [Abstract][Full Text] [Related]
59. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage.
Rawstron AC; Owen RG; Davies FE; Johnson RJ; Jones RA; Richards SJ; Evans PA; Child JA; Smith GM; Jack AS; Morgan GJ
Br J Haematol; 1997 Apr; 97(1):46-55. PubMed ID: 9136941
[TBL] [Abstract][Full Text] [Related]
60. Proliferation markers Ki-67 and p105 in soft-tissue lesions. Correlation with DNA flow cytometric characteristics.
Swanson SA; Brooks JJ
Am J Pathol; 1990 Dec; 137(6):1491-500. PubMed ID: 1979714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
